Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8427934 | 0.81 | ADORA3 (0.37) | ADORA3 | |
| SCHEMBL8429895 | 0.80 | PAK4 (0.42) | AURKAADORA3TTK | |
| SCHEMBL8426616 | 0.80 | PAK4 (0.37) | AURKAADORA3 | |
| SCHEMBL8429587 | 0.79 | ADORA3 (0.38) | AURKAADORA3MAPKAPK5 | |
| SCHEMBL12473231 | 0.79 | AURKA (0.34) | AURKAADORA3MAPKAPK5 | |
| SCHEMBL8429786 | 0.79 | BTK (0.34) | AURKA | |
| SCHEMBL8427744 | 0.78 | MAPKAPK5 (0.38) | AURKAADORA3MAPKAPK5 | |
| SCHEMBL8427933 | 0.76 | ZAP70 (0.35) | AURKABACE1BACE2ADORA3TTK | |
| SCHEMBL8427741 | 0.76 | BRD4 (0.39) | ADORA3TTK | |
| SCHEMBL14534281 | 0.76 | LRRK2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | AURKA 91/4885BACE1 3480/4885BACE2 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.